Literature DB >> 27686675

Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Deanna Saylor1, Arun Venkatesan2.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system (CNS) caused by the human neurotropic polyomavirus JC (JCV). The disease occurs virtually exclusively in immunocompromised individuals, and, prior to the introduction of antiretroviral therapy, was seen most commonly in the setting of HIV/AIDS. More recently, however, the incidence of PML in HIV-uninfected persons has increased with broader use of immunosuppressive and immunomodulatory medications utilized in a variety of systemic and neurologic autoimmune disorders. In this review, we discuss the epidemiology and clinical characteristics of PML in HIV-uninfected individuals, as well as diagnostic modalities and the limited treatment options. Moreover, we describe recent findings regarding the neuropathogenesis of PML, with specific focus on the unique association between PML and natalizumab, a monoclonal antibody that prevents trafficking of activated leukocytes into the CNS that is used for the treatment of multiple sclerosis.

Entities:  

Keywords:  Dimethyl fumarate; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; Systemic lupus erythematosus

Year:  2016        PMID: 27686675     DOI: 10.1007/s11908-016-0543-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  134 in total

1.  Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment.

Authors:  Yasuteru Sano; Yuta Nakano; Masatoshi Omoto; Masaki Takao; Eiji Ikeda; Atsunori Oga; Kazuo Nakamichi; Masayuki Saijo; Takashi Maoka; Hironori Sano; Motoharu Kawai; Takashi Kanda
Journal:  Intern Med       Date:  2015-04-15       Impact factor: 1.271

2.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

3.  Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy.

Authors:  Narendranath Epperla; Rafael Medina-Flores; Joseph J Mazza; Steven H Yale
Journal:  WMJ       Date:  2014-12

4.  Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET).

Authors:  A E Heald; J M Hoffman; J A Bartlett; H A Waskin
Journal:  Int J STD AIDS       Date:  1996 Aug-Sep       Impact factor: 1.359

Review 5.  Novel syndromes associated with JC virus infection of neurons and meningeal cells: no longer a gray area.

Authors:  Dhanashri P Miskin; Igor J Koralnik
Journal:  Curr Opin Neurol       Date:  2015-06       Impact factor: 5.710

6.  Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.

Authors:  Raija L P Lindberg; Lutz Achtnichts; Francine Hoffmann; Jens Kuhle; Ludwig Kappos
Journal:  J Neuroimmunol       Date:  2008-02-21       Impact factor: 3.478

7.  A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient.

Authors:  Shruti P Agnihotri; Christian Wuthrich; Xin Dang; David Nauen; Reza Karimi; Raphael Viscidi; Evelyn Bord; Stephanie Batson; Juan Troncoso; Igor J Koralnik
Journal:  Ann Neurol       Date:  2014-06-20       Impact factor: 10.422

8.  Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy.

Authors:  Dhanashri P Miskin; Susan T Herman; Long H Ngo; Igor J Koralnik
Journal:  J Neurovirol       Date:  2015-12-16       Impact factor: 2.643

9.  Identification and characterization of mefloquine efficacy against JC virus in vitro.

Authors:  Margot Brickelmaier; Alexey Lugovskoy; Ramya Kartikeyan; Marta M Reviriego-Mendoza; Norm Allaire; Kenneth Simon; Richard J Frisque; Leonid Gorelik
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

View more
  4 in total

1.  Discovery and characterization of novel trans-spliced products of human polyoma JC virus late transcripts from PML patients.

Authors:  A Sami Saribas; Julia DeVoto; Akhil Golla; Hassen S Wollebo; Martyn K White; Mahmut Safak
Journal:  J Cell Physiol       Date:  2017-12-18       Impact factor: 6.384

2.  Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.

Authors:  Fanny Huynh Du; Elizabeth A Mills; Yang Mao-Draayer
Journal:  Auto Immun Highlights       Date:  2017-11-16

3.  A human-derived 3D brain organoid model to study JC virus infection.

Authors:  Paula Barreras; David Pamies; Maria Chiara Monaco; Laura S Muñoz; Xiali Zhong; Eugene O Major; Helena T Hogberg; Thomas Hartung; Carlos A Pardo
Journal:  J Neurovirol       Date:  2022-03-03       Impact factor: 3.739

Review 4.  Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown.

Authors:  Heather E Moss
Journal:  Eye Brain       Date:  2017-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.